Stryker (NYSE:SYK) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Stryker (NYSE:SYK) issued its quarterly earnings results on Thursday. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20, Zacks reports. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter last year, the business posted $3.13 earnings per share. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker updated its FY 2026 guidance to 14.950-15.100 EPS.

Here are the key takeaways from Stryker’s conference call:

• Organic sales grew 9% in Q2, with high-single-digit growth in both MedSurg and Neurotechnology and Orthopaedics, while adjusted EPS increased 17.9% to $3.69.
• Strong demand for capital equipment produced an elevated backlog, and Stryker expects production recovery and fulfillment of orders to support a stronger second half.
• Mako installations reached a quarterly record, with rising utilization and the full U.S. launch of handheld Mako RPS adding to the company’s robotics growth opportunity; several other product launches also received positive customer feedback.
• Peripheral Vascular sales were hurt by a supply disruption at an Inari manufacturing plant, creating significant backorders and lost sales; the company expects improvement but said growth will take time to rebuild.
• Stryker narrowed 2026 guidance to 8.3%-9.3% organic sales growth and adjusted EPS of $14.95-$15.10, citing cybersecurity-related remediation and manufacturing costs despite improved margins and a planned resumption of share repurchases.

Stryker Trading Down 6.7%

Shares of Stryker stock traded down $23.19 during trading on Friday, reaching $324.85. 2,456,718 shares of the company were exchanged, compared to its average volume of 2,364,600. The business has a 50-day moving average price of $317.08 and a 200-day moving average price of $334.98. The firm has a market capitalization of $124.54 billion, a price-to-earnings ratio of 37.63, a P/E/G ratio of 2.26 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker has a twelve month low of $281.00 and a twelve month high of $401.99.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 40.74%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in shares of Stryker by 22.6% in the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares during the period. Corient Private Wealth LLC grew its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Stryker by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,074,606 shares of the medical technology company’s stock valued at $729,162,000 after acquiring an additional 30,151 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Stryker by 1.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,867,620 shares of the medical technology company’s stock worth $656,412,000 after acquiring an additional 27,377 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Stryker by 4.5% during the third quarter. Invesco Ltd. now owns 1,864,918 shares of the medical technology company’s stock worth $689,404,000 after purchasing an additional 80,536 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported second-quarter adjusted EPS of $3.69, above the $3.49 analyst consensus, while revenue rose 9.4% year over year to $6.59 billion, broadly matching expectations. Strong demand for orthopedic, spinal and other medical devices supported the results. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Organic sales growth reached approximately 9%, and management said operations are recovering from the cyber disruption. Stryker also plans to resume share repurchases, which could provide support for the stock. Stryker expects organic sales growth and adjusted EPS in 2026
• Positive Sentiment: Analysts remain generally constructive: BTIG maintained a “buy” rating with a $358 price target, while Truist raised its target to $340, although Truist kept a “hold” rating. BTIG Research updates Stryker price target
• Neutral Sentiment: Stryker forecast 2026 adjusted EPS of $14.95-$15.10 and organic sales growth of 8.3%-9.3%. The range remains close to consensus, but its narrower outlook gives investors less room for upside surprises. Stryker posts Q2 beats and narrows guidance
• Negative Sentiment: The stock’s decline reflects disappointment that the earnings beat did not translate into a stronger outlook. Investors remain concerned about the lingering financial and operational effects of the cyberattack, including the pace of the recovery and potential execution risks. SYK falls despite Q2 earnings beat

Analyst Ratings Changes

Several research firms have issued reports on SYK. Truist Financial upped their price objective on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday. Argus set a $370.00 target price on Stryker in a research report on Thursday, July 9th. Barclays cut their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Piper Sandler lowered their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Raymond James Financial set a $370.00 price objective on Stryker in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $389.88.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.